Navigation Links
Impact of stem cell transplantation location in brain a crucial factor for cell survival
Date:2/13/2013

Putnam Valley, NY. (Feb. 13, 2013) Researchers at the Johns Hopkins University in Baltimore, Md., and the Mossakowski Medical Research Centre in Warsaw, Poland, have found that nonself-donated cells (allografts) better survive implantation into the brains of immunocompetent research mice when the grafts are injected into the striatum (STR) of the brain rather than injected into the forceps minor (FM) region. In their study, all FM grafts were rejected while STR grafts accumulated and survived along the border between the striatum and the corpus callosum.

"To the best of our knowledge, this is the first demonstration that allograft survival within the central nervous system of an immunocompetent, non-immune suppressed host may be highly dependent on implantation site," said study co-author Dr. Pior Walczak of the Johns Hopkins University School of Medicine.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0888janowski.

The researchers, who assessed the grafted cells using bioluminescence for 16 days, reported that the distribution of the FM grafts was cylindrical, parallel to the needle track, while cells transplanted to the STR accumulated along the border between the striatum and the corpus callosum in a wedge-shaped, semi lunar "pocket." They suggested that the shape of the cell deposit in the FM was likely due to damage caused by the injection procedure.

"This is an indicator that surgical injury may be the leading factor initiating the rejection process," the researchers said. "Thus, minimally traumatic allograft transplantation, preventing activation of the microglia and limiting foreign antigen presentation, may contribute to long-term allograft survival."

They commented that the STR grafts were transplanted closer to the ventricles than were the FM grafts, suggesting that the lateral ventricles "appear to present a favorable microenvironment." Additionally, they hypothesized that variability in cell survival may be related to the differences in immune responses that may exist between white matter and grey matter, as the FM is the largest region of white matter while the STR is a grey matter structure.

"Our observation that immunorejection depends on the graft implantation site has important ramifications," said Dr. Walczak. "It may account for the variability in allograft survival reported by different research groups."

The accumulation of transplanted cells in the 'pocket' between two natural bordering regions of the brain, with minimal disruption to tissue integrity, appears the most plausible explanation for the dramatic difference in the allograft rejection rate, they wrote.

They concluded that the impact of the topographical and anatomical characteristics of the target site for allografting should be carefully considered when designing cell therapies for neurological disorders at both the pre-clinical and clinical levels.


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Physicians belief about obesity causes impacts advice and care
2. Climate change impacts to US coasts threaten public health, safety and economy
3. New study highlights impact of environmental change on older people
4. Going trayless study shows student impact
5. Clemson University researchers to study oil and gas operations impact on Gulf Coast pelicans
6. ImpactStory metrics of academic research outreach piloted by Pensoft Publishers
7. Study looks at gray seal impact on beach water quality
8. Ozone levels have sizeable impact on worker productivity
9. Grant funded to improve mothers nutrition before pregnancy and impact on baby
10. New online tool estimates carbon and energy impact of trees
11. Missing polar weather systems could impact climate predictions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 ... Billion by 2021, growing at a CAGR of 7.3% during the ... segment while hospitals and diagnostic laboratories segment accounted for the largest ... ... Complete report on global immunohistochemistry (IHC) market spread across 225 ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology: